Creso Pharma Limited Top Insiders
COPHFDelisted Stock | USD 0.12 0.00 0.00% |
Creso Pharma employs about 19 people. The company is managed by 10 executives with a total tenure of roughly 45 years, averaging almost 4.0 years of service per executive, having 1.9 employees per reported executive. Examination of Creso Pharma's management performance can provide insight into the company performance.
Christopher Grundy Insider Chief Officer |
Simon Buckingham Insider Consultant |
Creso |
Creso Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3818) % which means that it has lost $0.3818 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6678) %, meaning that it generated substantial loss on money invested by shareholders. Creso Pharma's management efficiency ratios could be used to measure how well Creso Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Creso Pharma Workforce Comparison
Creso Pharma Limited is rated fifth in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 240. Creso Pharma holds roughly 19.0 in number of employees claiming about 8% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (2.41) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.39. Creso Pharma Notable Stakeholders
A Creso Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Creso Pharma often face trade-offs trying to please all of them. Creso Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Creso Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher Grundy | Chief Officer | Profile | |
Simon Buckingham | Consultant | Profile | |
H Walker | Strategic Committee | Profile | |
MA MD | CoFounder Director | Profile | |
AICD DMgt | Ex Chairman | Profile | |
Gian Trepp | Commercial Director | Profile | |
ACIS ACIS | Joint Sec | Profile | |
CPA GAICD | Joint Sec | Profile | |
William BCom | MD CEO | Profile | |
Jodi Scott | Ex Operations | Profile |
About Creso Pharma Management Performance
The success or failure of an entity such as Creso Pharma Limited often depends on how effective the management is. Creso Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Creso management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Creso management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia. Creso Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Creso Pharma Workforce Analysis
Traditionally, organizations such as Creso Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Creso Pharma within its industry.Creso Pharma Manpower Efficiency
Return on Creso Pharma Manpower
Revenue Per Employee | 327.3K | |
Revenue Per Executive | 621.8K | |
Net Loss Per Employee | 1.6M | |
Net Loss Per Executive | 3M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Creso Pink Sheet
If you are still planning to invest in Creso Pharma Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Creso Pharma's history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |